Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T13:59:53.971Z Has data issue: false hasContentIssue false

Chapter 9 - Botulinum neurotoxin in oromandibular dystonia

Published online by Cambridge University Press:  05 February 2014

Roongroj Bhidayasiri
Affiliation:
Chulalongkorn Center of Excellence on Parkinson’s Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand
Francisco Cardoso
Affiliation:
Departament of Clinical Medine, Universidade Federal de Minas Gerais Belo Horizonte, Minas Gerais, Brazil
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Oromandibular dystonia (OMD) is a form of focal dystonia that involves the masticatory, lower facial, labial and lingual musculature. The term “cranial dystonia” is used when oromandibular dystonia occurs in association with blepharospasm. This particular combination is often referred to as Meige’s syndrome (reviewed by Bhidayasiri et al., 2006).

Epidemiology, clinical features and etiology

Oromandibular dystonia frequently affects women more than men and the prevalence was estimated to be around 68.9 cases per 1 million in the USA (Bhidayasiri et al., 2006). The mean age at onset is between 50 and 60 years. The involvement of masticatory muscles in OMD may cause jaw closing or jaw opening, lateral deviation, protrusion, retraction, or a combination of these. These movements often result in involuntary biting of the tongue, cheek or lips and difficulty with speaking and chewing. Its appearance is often socially embarrassing and disfiguring. In patients with jaw-closing OMD, dystonic spasms of the temporalis and masseter muscles may result in clenching or trismus and grinding of the teeth or bruxism. Jaw-opening OMD commonly involves the lateral pterygoids, anterior belly of the digastric muscle and other submental muscles; contractions of these muscles may lead to some degree of anterocollis. The effects of OMD may be alleviated by different proprioceptive sensory inputs (“sensory tricks”). These include touching the lips or chin, chewing gum or biting on a toothpick. Coexistence with dystonia in other regions and presences of sensory tricks is more common in jaw-opening than jaw-closing OMD. The contraction of mouth and pharynx muscles may cause involuntary vocalizations, occasionally confounded with vocal tics. In addition to the dystonic symptoms, many patients with OMD complain of tension-type headache, dental wear, temporomandibular joint syndrome and, more rarely, temperomandibular joint dislocation, resulting in upper airway collapse.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Benecke, R (2009). Xeomin in the treatment of cervical dystonia. Eur J Neurol, 16(Suppl. 2) 6–10.Google ScholarPubMed
Bhidayasiri, R, Cardoso, F, Truong, D (2006). Botulinum toxin in blepharospasm and oromandibular dystonia. Eur J Neurol, 13(Suppl 1), 21–9.CrossRefGoogle ScholarPubMed
Blitzer, A, Brin, MF, Greene, PE, Fahn, S (1989). Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol, 98, 93–7.CrossRefGoogle ScholarPubMed
Brin, MF (1994). Oromandibular dystonia: treatment of 96 patients with botulinum toxin type A. In Jankovic, J, Hallett, M (eds.) Therapy with Botulinum Toxin. New York: Marcel Dekker, pp. 429–35.Google ScholarPubMed
Brin, MF, Fahn, S, Moskowitz, C et al. (1987). Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord, 2, 237–54.CrossRefGoogle ScholarPubMed
Cardoso, F (2003). [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A.] Arq Neuropsiquiatr, 61, 607–10.Google ScholarPubMed
Clemente, C (1984). Muscles and fasciae. In Clemente, C (ed.) Gray’s Anatomy. Philadelphia, PA: Lea and Feabiger, pp. 429–605.Google Scholar
Hermanowicz, N, Truong, DD (1991). Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope, 101, 1216–18.CrossRefGoogle ScholarPubMed
Jankovic, J, Orman, J (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology, 37, 616–23.CrossRefGoogle ScholarPubMed
Laskawi, R, Rohrbach, S (2001). [Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin.] Laryngorhinootologie, 80, 708–13.CrossRefGoogle ScholarPubMed
National Institutes of Health (1991). National Institutes of Health Consensus Development Conference. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Statement, November 12–14, 1990. Arch Neurol, 48, 1294–8.CrossRefGoogle Scholar
Schneider, SA, Aggarwal, A, Bhatt, M et al. (2006). Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology, 67, 940–3.CrossRefGoogle ScholarPubMed
Tan, EK, Jankovic, J (1999). Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology, 53, 2102–7.CrossRefGoogle ScholarPubMed
Tan, EK, Jankovic, J (2000). Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry, 68, 186–90.CrossRefGoogle Scholar
Van den Bergh, P, Francart, J, Mourin, S, Kollmann, P, Laterre, EC (1995). Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve, 18, 720–9.CrossRefGoogle ScholarPubMed
Wan, XH, Vuong, KD, Jankovic, J (2005). Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci, J 20, 44–7.Google ScholarPubMed
WE MOVE Spasticity Study Group (2005). BTX-A Adult Dosing Guidelines. New York: WE MOVE (, accessed 21 May 2013).Google Scholar
Yoshida, K, Kaji, R, Kubori, T et al. (1998). Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord, 13, 699–705.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×